| Ytd | -45.13% | |
| 1y | -63.95% |
| Open | 3.33 | Prev Close | 3.37 | Low | 3.33 | High | 3.50 | Mkt Cap | 277.96M |
| Vol | 619.79K | Avg Vol | 859.08K | EPS | 0.19 | P/E | 18.37 | Forward P/E | N/A |
| Beta | 2.09 | Short Ratio | 3.35 | Inst. Own | 33.09% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-05 | 50-d Avg | 3.54 | 200-d Avg | 5.33 | 1yr Est | 14.90 |
NAGE News
LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Biotech--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global
LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Biotech--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global
Niagen Bioscience, Inc. (NAGE) Discusses Strategic Expansion Into Pharmaceutical Development and NB4
NB4168 is an oral small molecule therapy engineered to deliver substantially greater nicotinamide ri
https://www.sec.gov/Archives/edgar/data/1386570/000121390026077234/ea0297322-424b5_niagen.htm
NB4168, a patented therapeutic candidate designed to have significantly increased bioavailability an
U.S. stock futures up, Dow futures gain 0.1% as Snap (NYSE: SNAP) shares fall 10.5%, Fastly (NASDAQ:
U.S. stock futures lower, with Dow futures down 150 points. Fastenal shares dip 4% after meeting ear
Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleot
